Posttraumatic stress disorder (PTSD) is a DSM-5 diagnosis arising after exposure to actual or threatened death, serious injury, or sexual violence — characterized by intrusion symptoms, avoidance, negative alterations in cognition and mood, and altered arousal and reactivity. PTSD prevalence in Canadian adults is estimated at 9.2% lifetime / 2.4% past-year (Van Ameringen 2008; Statistics Canada). Specific populations have substantially higher rates: Canadian Armed Forces veterans (~11.1% in regular force, higher in deployed populations); first responders; nurses; corrections officers; survivors of intimate partner violence; refugees. This article is a Canadian evidence-and-pathway guide to psychedelic-assisted therapy options for PTSD: MDMA-AT (investigational under Health Canada SAP) with the strongest published RCT evidence; off-label ketamine with substantial real-world use particularly through VAC pathways; psilocybin with smaller emerging evidence base; and the federal funding and provincial first-responder pathways that determine practical access.
Key takeaways
- PTSD prevalence: ~9.2% lifetime / 2.4% past-year in Canadian adults. CAF regular force ~11.1%; substantially higher in deployed populations and first responders.
- MDMA-AT has the strongest published RCT evidence for PTSD: Mitchell 2021 Nature Medicine MAPP1 (PMID 33972795) and Mitchell 2023 Nature Medicine MAPP2 (PMID 37709999) — phase 3 trials. FDA Complete Response Letter August 2024 declined MDMA-AT for PTSD; further evidence required. Health Canada SAP remains accessible.
- Off-label ketamine for PTSD: substantial real-world use; Mithoefer 2018 phase 2 showed signal; KETOL Canadian multi-site ongoing.
- Psilocybin for PTSD: emerging; smaller evidence base than MDMA; some Canadian SAP applications.
- VAC has the most-developed Canadian PTSD coverage pathway: established for ketamine; case-by-case for MDMA-AT; psilocybin not covered. ~433 veterans on average each year (FY 2024-25, ~$10,109 per veteran).
- Bill 163 Ontario (expanded October 2024): presumptive PTSD coverage for designated first responders.
- WCB Alberta Bill 27 (2018): presumptive PTSD coverage for first responders.
- No psychedelic-assisted therapy is Health Canada-approved for PTSD. Spravato is approved for TRD only — not for PTSD.
Defining PTSD
DSM-5 PTSD criteria require:
- Criterion A: exposure to actual or threatened death, serious injury, or sexual violence
- Criterion B: intrusion symptoms (1+ of: distressing memories, nightmares, flashbacks, intense distress at cues, physiological reactivity at cues)
- Criterion C: persistent avoidance of trauma-related cues
- Criterion D: negative alterations in cognition and mood
- Criterion E: altered arousal and reactivity (hypervigilance, exaggerated startle, sleep disturbance)
- Criteria F-H: duration >1 month, functional impairment, not due to substance/medical condition
Complex PTSD (cPTSD) — ICD-11 distinction relevant to prolonged interpersonal trauma populations.
The PTSD evidence map for psychedelic-assisted therapy
MDMA-AT — strongest published evidence; investigational
- Mitchell 2021 Nature Medicine MAPP1 (PMID 33972795): phase 3 RCT of MDMA-AT for severe PTSD. 67% no longer met PTSD criteria at 18 weeks (MDMA arm) vs 32% (placebo+therapy).
- Mitchell 2023 Nature Medicine MAPP2 (PMID 37709999): replication confirming phase 3 efficacy.
- Mithoefer 2018 (PMID 29728331): phase 2 for service-related PTSD in active-duty service members and veterans.
- FDA Complete Response Letter August 2024: declined approval; required additional phase 3 evidence and trial design improvements. MDMA-AT is NOT approved by FDA or Health Canada.
- Health Canada SAP pathway: remains accessible for individual patient applications; case-by-case review.
- Lykos (formerly MAPS PBC) — sponsor; restructured after FDA CRL.
Off-label ketamine for PTSD — clinically used; modest evidence
- Feder 2014 (PMID 24515513): RCT of single-dose IV ketamine showing acute PTSD symptom reduction
- Feder 2021 (PMID 33387447): repeated-dose ketamine for chronic PTSD; some response signal
- Mithoefer service-related context: ketamine has been used in VAC pathways for veteran TRD with comorbid PTSD
- KETOL multi-site Canadian study: ongoing
- Real-world use: ketamine commonly used in Canadian KAP (ketamine-assisted psychotherapy) clinics for PTSD — though clinical effect sizes are smaller than for TRD
Psilocybin for PTSD — emerging
- Smaller evidence base than MDMA-AT; some Canadian SAP applications for PTSD (typically in patients who have failed other treatments)
- No published phase 3 RCTs in PTSD as of May 2026
Spravato — NOT for PTSD
Spravato (esketamine) is Health Canada-approved for treatment-resistant depression (TRD) only. It is not approved for PTSD. Patients should be cautious of providers framing Spravato as PTSD treatment.
For more detail see the MDMA-Assisted Therapy in Canada guide, MDMA-Assisted Therapy for Veterans, and Ketamine Therapy for PTSD.
Decision framework — comparing PTSD options
| Factor | MDMA-AT (SAP) | Off-label ketamine | Spravato | Psilocybin (SAP) |
|---|---|---|---|---|
| Health Canada approval | No (SAP investigational) | No (off-label; med approved as anaesthetic) | Approved for TRD only — NOT PTSD | No (SAP investigational) |
| Strongest PTSD RCT | Mitchell 2021/2023 phase 3 | Feder 2014/2021 | Not applicable | Smaller emerging |
| FDA status | CRL August 2024 | Generic; off-label | Approved (TRD) | Not approved |
| Insurance coverage | VAC case-by-case | Generally no | TRD only | No |
| Sessions to evaluate | 2-3 dosing sessions over weeks | 4-6 sessions typical | TRD label only | 1-2 dosing sessions |
| Psychotherapy required | Yes (always) | Variable | No (label) | Yes (always) |
| Veterans pathway | VAC case-by-case | VAC established | VAC if TRD comorbidity | VAC: not covered |
Canadian access pathways
Veterans (VAC)
VAC mental-health benefits cover psychedelic-assisted therapy for service-related conditions:
- Ketamine therapy: established case-by-case for service-related TRD, PTSD, chronic pain
- MDMA-AT: case-by-case for service-related PTSD where SAP-approved
- Psilocybin: not covered
- Spravato: covered for service-related TRD (Health Canada approved)
In FY2024-25, VAC reimbursed ~433 veterans an average of $10,109 each for psychedelic-assisted therapy.
For more detail see VAC Coverage for Psychedelic-Assisted Therapy and MDMA-Assisted Therapy for Veterans.
First responders — Bill 163 Ontario, Bill 27 Alberta
- Bill 163 Ontario (expanded October 2024): presumptive PTSD coverage for designated first responders (firefighters, police, paramedics, nurses, 911 dispatchers, corrections officers, wildland firefighters)
- WCB Alberta Bill 27 (2018): presumptive PTSD for first responders
- WSIB Ontario specialty formularies (Psychotraumatic, Serious Injury, Musculoskeletal, CNS/PNS, Chronic Pain Disability) cover ketamine and esketamine
- WCB Alberta covers ketamine for compensable PTSD case-by-case
For more detail see Workers' Compensation for Psychedelic-Assisted Therapy.
Civilian PTSD — pathways
- Spravato: covered for service-related TRD with PTSD comorbidity; not directly for PTSD
- Off-label ketamine: out-of-pocket dominantly; ~$400–$1,500/session
- MDMA-AT SAP: case-by-case Health Canada approval; minimal coverage
- Psilocybin SAP: case-by-case Health Canada approval
What the evidence does NOT say
- No psychedelic-assisted therapy is curative for PTSD. Mitchell 2023 MAPP2 67% no-longer-meeting-PTSD-criteria at 18 weeks is significant but not 100%.
- MDMA-AT is not FDA-approved. FDA CRL August 2024 declined approval; additional phase 3 evidence required. Patients pursuing MDMA-AT in Canada do so under SAP investigational pathway.
- Ketamine for PTSD has smaller effect sizes than for TRD. Feder 2021 showed signal but not the same magnitude as TRD evidence.
- First-line PTSD treatments — trauma-focused CBT (CPT, PE), EMDR, SSRIs (sertraline, paroxetine) — should typically be tried first. Psychedelic-assisted therapy is not a substitute for evidence-based trauma psychotherapy.
- Safety considerations: MDMA contraindicated with MAOIs, SSRIs (washout typically required), severe cardiac conditions; ketamine cardiovascular effects; psilocybin requires comprehensive screening for psychotic-disorder history.
- PTSD does not always respond. PTSD has a high non-response rate to all current treatments. Realistic patient expectations are critical.
How ATMA CENA works with PTSD patients
- Comprehensive intake: trauma history, prior treatments, medication interactions (MDMA + SSRI considerations), medical screen
- Three-phase model: preparation + dosing + integration
- coordinated care: trauma therapist remains primary therapeutic relationship
- Veteran/first-responder pathways: structured VAC and WSIB documentation support
For more detail on PTSD-specific options see the MDMA-Assisted Therapy in Canada guide, MDMA-Assisted Therapy for Veterans, and Ketamine Therapy for PTSD.
Frequently asked questions
What's the strongest evidence for PTSD psychedelic-assisted therapy? Mitchell et al. 2021 Nature Medicine MAPP1 and Mitchell et al. 2023 Nature Medicine MAPP2 phase 3 RCTs of MDMA-assisted therapy for PTSD. ~67% no-longer-meeting-PTSD-criteria at 18 weeks in the MDMA arm. FDA Complete Response Letter August 2024 declined approval; required additional evidence.
Can I access MDMA-AT in Canada? Through Health Canada SAP only — case-by-case review. The CDSA Schedule I status remains. Health Canada January 5, 2022 SAP amendment expanded the pathway for psychedelic-assisted psychotherapy applications.
Does Spravato treat PTSD? No. Spravato (esketamine) is Health Canada-approved for treatment-resistant depression (TRD), not PTSD. Patients should be cautious of providers framing Spravato as PTSD treatment.
What about veterans? VAC mental-health benefits cover psychedelic-assisted therapy for service-related conditions: ketamine therapy is established case-by-case; MDMA-AT case-by-case for SAP-approved PTSD; psilocybin is not covered.
What about first responders? Bill 163 Ontario (expanded October 2024) provides presumptive PTSD coverage for designated first responders. WCB Alberta Bill 27 (2018) parallels for AB. WSIB Ontario covers ketamine and esketamine on five specialty formularies.
What's the difference between MDMA-AT and ketamine for PTSD? MDMA-AT has the strongest published phase 3 RCT evidence (Mitchell 2021/2023). Ketamine for PTSD has smaller effect sizes (Feder 2014/2021) but is more accessible in Canada. MDMA-AT requires SAP application and is investigational; off-label ketamine is more clinically established.
What about complex PTSD? ICD-11 introduced complex PTSD as a distinct diagnosis. Most published RCTs have studied PTSD per DSM-5 criteria. Complex PTSD response patterns to psychedelic-assisted therapy are less well-characterized; clinical decisions should be individualized.
Should I try evidence-based trauma psychotherapy first? Generally yes. Trauma-focused cognitive behavioral therapy (CPT, prolonged exposure), EMDR, and SSRIs (sertraline, paroxetine) are first-line PTSD treatments with substantial evidence base. Psychedelic-assisted therapy is typically considered when these first-line treatments have not produced adequate response.
How does the FDA Complete Response Letter affect Canadian access? The FDA CRL applies to U.S. approval. Health Canada SAP remains accessible. Lykos (formerly MAPS PBC) restructured after the CRL and is preparing additional phase 3 evidence.
Is there a Canadian PTSD trial I can join?
Sources
- Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
- Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999.
- Mithoefer MC, Mithoefer AT, Feduccia AA, et al. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry, 5(6):486-497. PMID: 29728331.
- Feder A, Parides MK, Murrough JW, et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71(6):681-8. PMID: 24515513.
- Feder A, Costi S, Rutter SB, et al. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry, 178(2):193-202. PMID: 33387447.
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
- WSIB Ontario — Ketamine and Esketamine Formulary Decision: https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
- WSIB Ontario — PTSD First Responders Policy: https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
- WCB Alberta — Bill 27 / first responder presumptive PTSD: https://www.wcb.ab.ca/
- Lykos Therapeutics: https://lykospbc.com/
- American Psychological Association PTSD treatment guideline: https://www.apa.org/ptsd-guideline
- Van Ameringen M, Mancini C, Patterson B, Boyle MH. (2008). Post-traumatic stress disorder in Canada. CNS Neurosci Ther, 14(3):171-81. PMID: 18801109.
- CDSA Schedule I — MDMA: https://laws-lois.justice.gc.ca/eng/acts/c-38.8/
Related articles
- MDMA-Assisted Therapy in Canada
- MDMA-Assisted Therapy for Veterans
- Ketamine Therapy for PTSD
- VAC Coverage for Psychedelic-Assisted Therapy
- Workers' Compensation for Psychedelic-Assisted Therapy
- Treatment-Resistant Depression and Psychedelic-Assisted Therapy
- Insurance Coverage for Psychedelic-Assisted Therapy in Canada
- Is MDMA Therapy Legal in Canada?
Last updated: 2026-05-06